Interim Data for Phase 3 Graft-versus-Host Disease Trial Looks Promising
According to a story from PR Newswire, the specialty pharmaceutical company Mallinckrodt plc recently announced the release of interim data from the company's Phase 3 clinical trial. This trial is…